CDKN2A/B [15]), amplifications (e.g. JUN in liposarcoma [16]), fusion partners (e.g. PAX3/7::FOXO1 in rhabdomyosarcoma [17]), breakpoint positions in fusions (e.g. NAB2::STAT6 in SFT [14]) and the extent of segmental (i.e. sub-chromosomal arm) copy number changes (e.g. synovial sarcoma [18]) (Fig. 2). This evidence concerns the gene NAB2 and synovial sarcoma.